XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 116,222 $ 143,663
Accounts receivable 488 488
Prepaid expenses 17,060 17,434
Other current assets 283 169
Total current assets 134,053 161,754
Property, equipment, and software—net 23,874 25,154
Intangible assets—net 2,021 2,048
Right-of-use assets—net 3,892 4,180
Investment in equity securities 3,091 3,091
Equity method investments 2,799 3,751
Note receivable—net 6,966 6,879
Other assets 4,655 4,641
Total assets 181,351 211,498
Current liabilities:    
Accounts payable 699 1,144
Accrued compensation 3,154 6,765
Accrued clinical and research and development expenses 2,073 4,028
Deferred revenue 19,686 21,244
Lease liabilities 1,874 1,822
Other current liabilities 1,620 977
Total current liabilities 29,106 35,980
Deferred revenue 65,743 67,015
Lease liabilities 4,327 4,813
Long term debt—net 2,482 2,478
Contract liabilities 10,000 10,000
Other noncurrent liabilities 34 44
Total liabilities 111,692 120,330
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.0001 par value— 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; no shares issued and outstanding as of March 31, 2022 and December 31, 2021
Common stock; $0.000005 par value— 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 62,585,043 shares issued and 61,774,571 shares outstanding as of March 31, 2022; 61,712,577 shares issued and 60,902,105 shares outstanding as of December 31, 2021
Additional paid-in capital 415,454 408,795
Accumulated deficit (344,843) (316,675)
Treasury stock (952) (952)
Total stockholders’ equity 69,659 91,168
Total liabilities and stockholders’ equity $ 181,351 $ 211,498